Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies
Compass Therapeutics
Compass Therapeutics
Tango Therapeutics, Inc.
Travera Inc
Seagen Inc.
Genmab
KaliVir Immunotherapeutics
Tango Therapeutics, Inc.
Beijing Biotech
IDEAYA Biosciences
Vivace Therapeutics, Inc
AstraZeneca
iOnctura
Sotio Biotech Inc.
Endeavor Biomedicines, Inc.
Nuvectis Pharma, Inc.
A2 Biotherapeutics Inc.
A2 Biotherapeutics Inc.
Takeda
Lumicell, Inc.
Perspective Therapeutics
Seagen Inc.
Novartis
Kezar Life Sciences, Inc.
VM Oncology, LLC
Bristol-Myers Squibb
NeoTX Therapeutics Ltd.
HiFiBiO Therapeutics
Ipsen
Incyte Corporation
Actym Therapeutics, Inc.
Merck Sharp & Dohme LLC
Novartis
TCR2 Therapeutics
TCR2 Therapeutics
Incyte Corporation
Incyte Corporation
Merck Sharp & Dohme LLC
A2 Biotherapeutics Inc.
Incyte Corporation
PharmaMar
Turnstone Biologics, Corp.
Taiho Oncology, Inc.
Ipsen
Deciphera Pharmaceuticals, LLC
Taproot Health
Symphogen A/S
Travera Inc
Aromics Therapeutics
Molecular Templates, Inc.
NGM Biopharmaceuticals, Inc